Skip to main content

Table 3 Characteristics of patients receiving different drug regimens in the continuation phase

From: Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure

  INH + Rifampicin INH + Rifampicin + ethambutol
Age in years, median, (range) 25 (16–75) 25 (16–76)
Sex, n/N (%)
 Male 46/103 (44.6) 48/101 (47.5)
 Female 57/103 (55.3) 53/101 (52.4)
History of contact with TB, n/N (%)
a Recent 21/103 (20.3) 20/101 (19.8)
b Previous 17/103 (16.5) 22/101 (21.7)
 No history of contact 65/103 (63.1) 59/101 (58.4)
Prevalence of HIV 0/103 0/103
Smoker n/N (%) 4/103 (3.8) 10/101 (9.9)
Prevalence of diabetes n/N (%) 8/103 (7.7) 3/101 (2.9)
cBacillary load before treatment n/N (%)
 scanty 10/103 (9.7) 10/101 (9.9)
  + 1 57/103 (55.4) 60/101 (59.4)
  + 2 25/103 (24.2) 12/101 (11.9)
  + 3 11/103 (10.7) 19/101 (18.8)
Chest X-ray n/N (%)
 Cavitary lesions 3/7 (42.9) 4/7 (57.1)
 Non-cavitary infiltrates 49/95 (51.6) 46/95 (48.4)
 Not available 50/102 (49.1) 52/102 (50.9)
  1. n number, N Total number, % percentage
  2. aHistory of contact with active TB case during the course of diagnosis and treatment
  3. bHistory of contact with active TB case before diagnosis and treatment
  4. cGraded as per guidelines of the International Union Against Tuberculosis and Lung Disease